BioCryst Presents New Real-World Evidence Showing Reduced Angioedema-Related Medical Visits After Switching to ORLADEYO® (berotralstat) at ACAAI 2026 Annual Scientific Meeting
BioCryst Pharma Announces New Real-World Evidence On Use Of Once-Daily ORLADEYO For Patients With Hereditary Angioedema, Showing Reductions In Hospitalizations And Emergency Department Visits
BioCryst Pharmaceuticals (BCRX) Raised Its Outlook, Is It Still Below Fair Value?
BioCryst Pharmaceuticals, Inc. 2026 Q3 - Results - Earnings Call Presentation
Wedbush Maintains Outperform on BioCryst Pharma, Lowers Price Target to $17
BioCryst Pharmaceuticals Inc (BCRX) (Q3 2026) Earnings Call Highlights: ORLADEYO Revenue Climbs ...
BioCryst to Present at Upcoming Investor Conferences
BioCryst Pharmaceuticals, Inc. Q3 2026 Earnings Call Summary
BioCryst (BCRX) Q3 2026 Earnings Call Transcript
BioCryst Pharmaceuticals Q3 Earnings Call Highlights
BioCryst Pharmaceuticals, Inc. (BCRX) Q3 2026 Earnings Call Transcript
BioCryst: Solid Q3 Earnings, But Long-Acting HAE Data Due 2027 The Key Catalyst
BioCryst Pharmaceuticals (BCRX) Surpasses Q3 Earnings and Revenue Estimates
BioCryst: Q3 Earnings Snapshot
BioCryst Reports Third Quarter 2026 Financial Results
BioCryst Pharma Q3 2026 Earnings Call Transcript
BioCryst Pharma Raises FY2026 Sales Guidance from $690.000M-$715.000M to $715.000M-$730.000M vs $710.134M Est
How New HAE Data At BioCryst Pharmaceuticals Stock Has Changed Its Investment Story
Wall Street Analysts See a 137.91% Upside in BioCryst (BCRX): Can the Stock Really Move This High?
BioCryst to Present New Data for ORLADEYO® (berotralstat) and Navenibart at the 2026 American College of Allergy, Asthma & Immunology Annual Scientific Meeting
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.